CY1121728T1 - Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα - Google Patents
Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακαInfo
- Publication number
- CY1121728T1 CY1121728T1 CY20191100606T CY191100606T CY1121728T1 CY 1121728 T1 CY1121728 T1 CY 1121728T1 CY 20191100606 T CY20191100606 T CY 20191100606T CY 191100606 T CY191100606 T CY 191100606T CY 1121728 T1 CY1121728 T1 CY 1121728T1
- Authority
- CY
- Cyprus
- Prior art keywords
- glycosaminoglycan
- derivatives
- medicines
- desulfurized
- glucosaminoglycans
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 2
- 229940127215 low-molecular weight heparin Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 229920002971 Heparan sulfate Polymers 0.000 abstract 1
- 102100024025 Heparanase Human genes 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 150000002009 diols Chemical group 0.000 abstract 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract 1
- 108010037536 heparanase Proteins 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Η εφεύρεση αφορά σε Ν-αποθειωμένα και προαιρετικώς 2-Ο-αποθειωμένα παράγωγα γλυκοζαμινογλυκάνης, όπου τουλάχιστον τμήμα των γειτονικών διολών και ΟΗ/ΝΗ2 έχουν μετατραπεί προς την αντίστοιχη αλδεΰδη, οι οποίες αλδεΰδες έχουν στη συνέχεια αναχθεί προς την αντίστοιχη αλκοόλη. Αυτά τα προϊόντα είναι προικισμένα με ανασταλτική δραστικότητα ηπαρανάσης και κατά του όγκου δραστικότητα. Τα εν λόγω παράγωγα γλυκοζαμινογλυκάνης λαμβάνονται από φυσική ή συνθετική γλυκοζαμινογλυκάνη, κατά προτίμηση από μη-κλασματωμένη ηπαρίνη, χαμηλού μοριακού βάρους ηπαρίνες (LMWHs), θειική ηπαράνη ή παράγωγα αυτών. Η εφεύρεση περαιτέρω αφορά στη μέθοδο παρασκευής αυτών και περαιτέρω στη χρήση αυτών ως δραστικά συστατικά φαρμάκων, επίσης σε συνδυασμό με γνωστά καθιερωμένα φάρμακα ή θεραπείες. Η παρούσα εφεύρεση περαιτέρω αφορά σε μία μέθοδο για διάσπαση της διασύνδεσης C2-C3 υπολειμμάτων γλυκοζαμίνης μιας γλυκοζαμινογλυκάνης με οξείδωση της εν λόγω γλυκοζαμινογλυκάνης.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000005A ITLO20130005A1 (it) | 2013-10-31 | 2013-10-31 | Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci |
PCT/EP2014/072707 WO2015062951A1 (en) | 2013-10-31 | 2014-10-23 | Derivatives of n-desulfated glucosaminoglycans and use as drugs |
EP14798720.0A EP3063177B1 (en) | 2013-10-31 | 2014-10-23 | Derivatives of n-desulfated glycosaminoglycans and use as drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121728T1 true CY1121728T1 (el) | 2020-07-31 |
Family
ID=49683857
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181100940T CY1121087T1 (el) | 2013-10-31 | 2018-09-10 | Παραγωγα ν-αποθειωμενων γλυκοζαμινογλυκανων και χρηση ως φαρμακα |
CY20191100606T CY1121728T1 (el) | 2013-10-31 | 2019-06-07 | Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181100940T CY1121087T1 (el) | 2013-10-31 | 2018-09-10 | Παραγωγα ν-αποθειωμενων γλυκοζαμινογλυκανων και χρηση ως φαρμακα |
Country Status (14)
Country | Link |
---|---|
US (2) | US10875936B2 (el) |
EP (2) | EP3063177B1 (el) |
JP (1) | JP6753610B2 (el) |
KR (1) | KR102007554B1 (el) |
CN (2) | CN108912237B (el) |
CY (2) | CY1121087T1 (el) |
DK (2) | DK3375792T3 (el) |
ES (2) | ES2687900T3 (el) |
HK (2) | HK1222873A1 (el) |
IT (1) | ITLO20130005A1 (el) |
PL (2) | PL3375792T3 (el) |
PT (2) | PT3375792T (el) |
TR (1) | TR201908669T4 (el) |
WO (1) | WO2015062951A1 (el) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11225531B2 (en) | 2018-02-02 | 2022-01-18 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | Glycosaminoglycan derivative and preparation method therefor and use thereof |
CN111019014A (zh) * | 2019-11-22 | 2020-04-17 | 苏州二叶制药有限公司 | 一种那曲肝素钙的制备工艺 |
CN114901702B (zh) * | 2019-12-27 | 2024-01-09 | 深圳市海普瑞药业集团股份有限公司 | 一种糖胺聚糖衍生物及其应用 |
WO2024012972A1 (en) | 2022-07-14 | 2024-01-18 | Centro Alta Tecnologia Istituto Di Ricerche Chimiche E Biochimiche G. Ronzoni S.R.L. | Synthetic hexasaccharides mimics of heparin showing heparanase inhibition activity |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1230582B (it) | 1988-10-21 | 1991-10-28 | Opocrin S P A Lab Farmabiologi | Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica |
US5250519A (en) * | 1991-03-29 | 1993-10-05 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
US5296471A (en) * | 1992-12-22 | 1994-03-22 | Glycomed Incorporated | Method for controlling o-desulfation of heparin and compositions produced thereby |
US5583121A (en) * | 1994-01-12 | 1996-12-10 | Michigan State University | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes |
IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
CN1197587C (zh) | 2000-06-09 | 2005-04-20 | 中国科学院上海细胞生物学研究所 | N-位脱硫酸肝素在预防和治疗炎症中的应用 |
PT1427427E (pt) | 2001-09-12 | 2011-09-13 | Sigma Tau Res Switzerland Sa | Derivados de glicosaminoglicanos parcialmente dessulfatados como inibidores da heparanase, dotados de actividade antiangiogénica e destituídos de efeito anticoagulante |
US8071569B2 (en) * | 2002-09-20 | 2011-12-06 | Mousa Shaker A | Oxidized heparin fractions and their use in inhibiting angiogenesis |
CN102924627A (zh) | 2012-11-19 | 2013-02-13 | 江南大学 | 一种具有抗肿瘤活性的低抗凝肝素的制备方法 |
-
2013
- 2013-10-31 IT IT000005A patent/ITLO20130005A1/it unknown
-
2014
- 2014-10-23 DK DK18170785.2T patent/DK3375792T3/da active
- 2014-10-23 DK DK14798720.0T patent/DK3063177T3/en active
- 2014-10-23 US US15/032,248 patent/US10875936B2/en active Active
- 2014-10-23 PT PT18170785T patent/PT3375792T/pt unknown
- 2014-10-23 CN CN201811112516.XA patent/CN108912237B/zh active Active
- 2014-10-23 PL PL18170785T patent/PL3375792T3/pl unknown
- 2014-10-23 WO PCT/EP2014/072707 patent/WO2015062951A1/en active Application Filing
- 2014-10-23 JP JP2016550978A patent/JP6753610B2/ja active Active
- 2014-10-23 EP EP14798720.0A patent/EP3063177B1/en active Active
- 2014-10-23 KR KR1020167012046A patent/KR102007554B1/ko active IP Right Grant
- 2014-10-23 PL PL14798720T patent/PL3063177T3/pl unknown
- 2014-10-23 EP EP18170785.2A patent/EP3375792B9/en active Active
- 2014-10-23 ES ES14798720.0T patent/ES2687900T3/es active Active
- 2014-10-23 PT PT14798720T patent/PT3063177T/pt unknown
- 2014-10-23 CN CN201480060135.5A patent/CN105814086B/zh active Active
- 2014-10-23 TR TR2019/08669T patent/TR201908669T4/tr unknown
- 2014-10-23 ES ES18170785T patent/ES2731582T3/es active Active
-
2016
- 2016-09-20 HK HK16111021.2A patent/HK1222873A1/zh unknown
-
2018
- 2018-09-10 CY CY181100940T patent/CY1121087T1/el unknown
- 2018-10-31 HK HK18113904.8A patent/HK1254817B/zh unknown
-
2019
- 2019-06-07 CY CY20191100606T patent/CY1121728T1/el unknown
-
2020
- 2020-03-18 US US16/823,068 patent/US11248063B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CY1121087T1 (el) | 2019-12-11 |
EP3375792B9 (en) | 2019-11-13 |
CN105814086A (zh) | 2016-07-27 |
EP3063177B1 (en) | 2018-08-15 |
DK3375792T3 (da) | 2019-06-24 |
EP3375792B1 (en) | 2019-05-15 |
PT3063177T (pt) | 2018-10-19 |
US11248063B2 (en) | 2022-02-15 |
ES2687900T3 (es) | 2018-10-29 |
PL3375792T3 (pl) | 2019-09-30 |
CN108912237B (zh) | 2021-04-13 |
HK1254817B (zh) | 2020-03-27 |
PT3375792T (pt) | 2019-06-27 |
US10875936B2 (en) | 2020-12-29 |
US20210332162A9 (en) | 2021-10-28 |
HK1222873A1 (zh) | 2017-07-14 |
WO2015062951A1 (en) | 2015-05-07 |
ES2731582T3 (es) | 2019-11-18 |
US20210054108A2 (en) | 2021-02-25 |
KR102007554B1 (ko) | 2019-08-05 |
EP3375792A1 (en) | 2018-09-19 |
CN108912237A (zh) | 2018-11-30 |
JP6753610B2 (ja) | 2020-09-09 |
TR201908669T4 (tr) | 2019-07-22 |
JP2017507210A (ja) | 2017-03-16 |
US20200216577A1 (en) | 2020-07-09 |
EP3063177A1 (en) | 2016-09-07 |
DK3063177T3 (en) | 2018-10-08 |
KR20160105969A (ko) | 2016-09-08 |
CN105814086B (zh) | 2018-09-28 |
PL3063177T3 (pl) | 2018-11-30 |
US20160237178A1 (en) | 2016-08-18 |
ITLO20130005A1 (it) | 2015-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121728T1 (el) | Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα | |
MX2019006868A (es) | Derivados de polisacáridos anfifílicos y composiciones que los comprenden. | |
BR112015028603A2 (pt) | método para produção de um produto de biomaterial, e, uso de um material composto | |
BR112014003477A2 (pt) | composições imunoterapêuticas de levedura-muc1 e usos das mesmas | |
CY1120197T1 (el) | Ηπαρινες χαμηλης αντιπηκτικης δρασης | |
GB2535414A (en) | Sanitary tissue products with superior machine direction elongation and foreshortening properties and methods for making same | |
UY35508A (es) | Derivados de oxopiridina sustituidos | |
WO2012092336A3 (en) | Molecular profiling for cancer | |
CY1122822T1 (el) | Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο | |
BR112013025862A2 (pt) | composições de lignina, métodos de produzir as composições, métodos de utilizar composições de lignina e produtos produzidos desse modo | |
MX351104B (es) | Nuevos glucosaminoglucanos con baja actividad anticoagulante. | |
BR112015014876A2 (pt) | composições e métodos para aperfeiçoar a solubilidade de rebaudiosídeo x | |
CY1125071T1 (el) | Θεραπεια του συνδρομου ευθραυστου χ με κανναβιδιολη | |
BR112017005997A2 (pt) | método | |
CY1121515T1 (el) | Μεθοδοι και συνθεσεις για την επουλωση πληγων | |
UA113005C2 (uk) | Біотехнологічний хондроїтин-6-сульфат з низькою молекулярною масою для запобігання остеоартриту | |
BR112015012198A2 (pt) | método de preparação de fibras à base do derivado c11-c18 acilatado de hialuronano nos grupos hidroxila do ácido hialurônico, fibra baseada no derivado c11-c18 acilatado de hialuronano nos grupos hidroxila do ácido hialurônico, uso da fibra, têxtil e uso dos têxteis à base das fibras | |
TR201901472T4 (tr) | Kondroitin sülfat ve hiyalüronik asit türevlerini içeren farmasötik formülasyonlar. | |
BR112012013119A2 (pt) | derivados de 1-amino-piperidina-pirrolidina-diona espirocondensada com atividade pesticida. | |
WO2013050300A3 (en) | Depolymerisation of polysaccharides and related products | |
CY1121859T1 (el) | Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης | |
CY1121427T1 (el) | Χρηση ενος μοριου mir172 για τη μειωση της φλεγμονhς | |
BR112018009225A2 (pt) | conjugados de anticorpo anti-cd22-maitansina e métodos de uso dos mesmos | |
CY1123044T1 (el) | Νεες ενωσεις | |
BR112018012647A2 (pt) | composto, método para tratamento de um hospedeiro, e, uso de um composto. |